...
首页> 外文期刊>Bioorganic and Medicinal Chemistry Letters >Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors: Synthesis, SAR, and in vivo antitumor activity.
【24h】

Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors: Synthesis, SAR, and in vivo antitumor activity.

机译:酰基脲连接的直链异羟肟酸酯作为新型组蛋白脱乙酰基酶抑制剂:合成,SAR和体内抗肿瘤活性。

获取原文
获取原文并翻译 | 示例

摘要

Thirty-six novel acylurea connected straight chain hydroxamates were designed and synthesized. Structure-activity relationships (SAR) were established for the length of linear chain linker and substitutions on the benzoylurea group. Compounds 5g, 5i, 5n, and 19 showed 10-20-fold enhanced HDAC1 potency compared to SAHA. In general, the cellular potency pIC(50) (COLO205) correlates with enzymatic potency pIC(50) (HDAC1). Compound 5b (SB207), a structurally simple and close analogue to SAHA, is more potent against HDAC1 and HDAC6 compared to the latter. As a representative example of this series, good in vitro enzymatic and cellular potency plus an excellent pharmacokinetic profile has translated into better efficacy than SAHA in both prostate cancer (PC3) and colon cancer (HCT116) xenograft models.
机译:设计并合成了36种新型酰基脲连接的直链异羟肟酸酯。建立了结构活性关系(SAR)的线性链接头的长度和苯甲酰脲基上的取代。与SAHA相比,化合物5g,5i,5n和19显示出增强的HDAC1效力10-20倍。通常,细胞效能pIC(50)(COLO205)与酶效能pIC(50)(HDAC1)相关。化合物5b(SB207)是SAHA的结构简单且紧密相似的化合物,与后者相比,它对HDAC1和HDAC6更有效。作为该系列的代表性实例,在前列腺癌(PC3)和结肠癌(HCT116)异种移植模型中,良好的体外酶促和细胞效力以及出色的药代动力学特性已转化为比SAHA更好的疗效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号